Sp1128

CLINICAL CHARACTERISTICS OF PAIN IN PATIENTS WITH ACTIVE IBD AND DURING REMISSION

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

Visceral pain is a leading cause of disability worldwide, affecting 20% of the population. Increased sensitivity to normal innocuous stimuli in the intestine is a hallmark of many organic and functional gastrointestinal disorders. A better understanding of the mechanisms associated with visceral hypersensitivity whether they include peripheral (eg microbiome-diet) or central inputs is necessary and critical in order to be able to treat patients. This workshop will present and discuss recent advances in our understanding of the factors that stimulate nociceptors of the intestine, and further central sensitization. Among the mechanisms that will be discussed are microbial factors, epithelial factors, immune mediators, and neuro-immune interactions, all studied in the setting of models, but also in patients' cohorts. This workshop is timely since cohorts of IBD patients are on-going aiming at phenotyping pain in such patients, and further identifying mechanisms associated with abdominal pain. Recent calls from national and international charities are supporting research on visceral pain, recognizing chronic pain as a priority research area. The implication of findings and potential treatments discussed should be of interest to a broad array of researchers from industrial, clinical and basic research background.

Presenter

Speaker Image for Qasim Aziz
Barts and The London School of Medicine and Dentistry, Queen Mary, University of London UK

Tracks

Related Products

Thumbnail for AGA Gut-Brain Communication
AGA Gut-Brain Communication
Gathering evidence suggests that communication between the gut and brain plays a major role in health and disease. However, our understanding of the mechanisms underlying gut-brain communication is a major unresolved field of neurogastroenterology…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…